AGP Executive Report
Last update: an hour agoBladder Cancer Breakthrough: The EU CHMP has issued a positive opinion for pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) as perioperative treatment for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with a final EU decision expected in Q3 2026—relevant for patients in Iceland, Liechtenstein and Norway too. Rare Immunodeficiency Access: The European Commission granted marketing authorization for Pharming’s Joenja (leniolisib) for activated PI3K delta syndrome (APDS) in patients aged 12+; first European launch is expected in Germany in Q3 2026, with coverage across the EU plus Norway, Iceland and Liechtenstein. STI Warning for Europe: New ECDC data shows record-high STI levels across EU countries plus Iceland, Liechtenstein and Norway, with gonorrhoea, syphilis and chlamydia all rising—an urgent reminder to use protection and get tested. Data Privacy Check: A review of Incogni says the data-removal service can contact 420+ data brokers and has processed millions of deletion requests, but readers should still weigh subscription costs and what’s actually covered. Travel Health & Safety: UK rules warn travellers not to bring meat or dairy from the EU, with undeclared items risking confiscation and fines up to £5,000.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[EU CHMP Issues Positive Opinion for Perioperative Pembrolizumab/Enfortumab Vedotin in Cisplatin-Ineligible MIBC]]>](https://cdn.sanity.io/images/0vv8moc6/onclive/c32607911ff8c2b81ea841493078c23b4f97815c-1280x720.jpg)
